Search research articles
Contact Us
Filters
Showing results (21-30 of 49) with videos related to
Page
of 5
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 6, 2024
Pharmacologically inducing anoikis offers novel therapeutic opportunities in hepatocellular carcinoma
Yumin Wang, Joshua S Fleishman, Jinhua Wang, et al.
Drug Discovery Today
|
June 27, 2024
New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma
Fei-Mu Fan, Joshua S Fleishman, Jin Chen, et al.
Cancer
|
February 19, 1999
Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?
J E Herndon, S Fleishman, A B Kornblith, et al.
Drug Design, Development and Therapy
|
February 19, 2025
NLRP3 Inflammasome Targeting Offers a Novel Therapeutic Paradigm for Sepsis-Induced Myocardial Injury
Yuzi Jin, Joshua S Fleishman, Yudong Ma, et al.
Frontiers in Pharmacology
|
February 5, 2024
Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
Yumin Wang, Joshua S Fleishman, Tongda Li, et al.
Molecular Cancer
|
August 27, 2024
Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
Hongquan Wang, Joshua S Fleishman, Sihang Cheng, et al.
Molecular Cancer
|
April 16, 2026
Retraction Note: Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
Hongquan Wang, Joshua S Fleishman, Sihang Cheng, et al.
Antioxidants & Redox Signaling
|
May 23, 2025
Small Molecules Targeting Non-Coding RNAs Regulating Ferroptosis: New Opportunities in Precision Cancer Therapy
Junjing Zhang, Yan Wang, Joshua S Fleishman, et al.
Ageing Research Reviews
|
February 15, 2025
cGAS-STING targeting offers novel therapeutic opportunities in neurological diseases
Hongquan Wang, Joshua S Fleishman, Shuang Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1995
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials
C L Bennett, T J Smith, S L George, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 49) with videos related to
Sort By:
Page
of 5
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 6, 2024
Pharmacologically inducing anoikis offers novel therapeutic opportunities in hepatocellular carcinoma
Yumin Wang, Joshua S Fleishman, Jinhua Wang, et al.
Drug Discovery Today
|
June 27, 2024
New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma
Fei-Mu Fan, Joshua S Fleishman, Jin Chen, et al.
Cancer
|
February 19, 1999
Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?
J E Herndon, S Fleishman, A B Kornblith, et al.
Drug Design, Development and Therapy
|
February 19, 2025
NLRP3 Inflammasome Targeting Offers a Novel Therapeutic Paradigm for Sepsis-Induced Myocardial Injury
Yuzi Jin, Joshua S Fleishman, Yudong Ma, et al.
Frontiers in Pharmacology
|
February 5, 2024
Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
Yumin Wang, Joshua S Fleishman, Tongda Li, et al.
Molecular Cancer
|
August 27, 2024
Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
Hongquan Wang, Joshua S Fleishman, Sihang Cheng, et al.
Molecular Cancer
|
April 16, 2026
Retraction Note: Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
Hongquan Wang, Joshua S Fleishman, Sihang Cheng, et al.
Antioxidants & Redox Signaling
|
May 23, 2025
Small Molecules Targeting Non-Coding RNAs Regulating Ferroptosis: New Opportunities in Precision Cancer Therapy
Junjing Zhang, Yan Wang, Joshua S Fleishman, et al.
Ageing Research Reviews
|
February 15, 2025
cGAS-STING targeting offers novel therapeutic opportunities in neurological diseases
Hongquan Wang, Joshua S Fleishman, Shuang Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1995
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials
C L Bennett, T J Smith, S L George, et al.
Page
of 5